A detailed history of Morgan Stanley transactions in Genenta Science S.P.A. stock. As of the latest transaction made, Morgan Stanley holds 500 shares of GNTA stock, worth $2,550. This represents 0.0% of its overall portfolio holdings.

Number of Shares
500
Previous 500 -0.0%
Holding current value
$2,550
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022

BUY
$5.39 - $8.26 $2,695 - $4,130
500 New
500 $4,000

Others Institutions Holding GNTA

About Genenta Science S.p.A.


  • Ticker GNTA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,216,900
  • Market Cap $92.9M
  • Description
  • Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated...
More about GNTA
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.